64730-34-3 Usage
Description
4-(7-METHYLIMIDAZO[1,2-A]PYRIDIN-2-YL)ANILINE is a chemical compound belonging to the class of anilines, characterized by its molecular formula C14H12N4 and a molecular weight of 236.27 g/mol. As a derivative of the imidazo[1,2-a]pyridine, it features a substituted aniline ring, which makes it a valuable component in the synthesis of pharmaceuticals and agrochemicals. Its potential biological activities and applications are currently under investigation in the field of medicinal chemistry.
Uses
Used in Pharmaceutical Synthesis:
4-(7-METHYLIMIDAZO[1,2-A]PYRIDIN-2-YL)ANILINE is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Development:
In the agrochemical industry, 4-(7-METHYLIMIDAZO[1,2-A]PYRIDIN-2-YL)ANILINE is utilized as a building block in the creation of novel agrochemicals, potentially enhancing crop protection and yield.
Used in Medicinal Chemistry Research:
4-(7-METHYLIMIDAZO[1,2-A]PYRIDIN-2-YL)ANILINE serves as a subject of research in medicinal chemistry, where its biological activities are being explored to understand its potential role in the treatment or management of various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 64730-34-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,4,7,3 and 0 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 64730-34:
(7*6)+(6*4)+(5*7)+(4*3)+(3*0)+(2*3)+(1*4)=123
123 % 10 = 3
So 64730-34-3 is a valid CAS Registry Number.
InChI:InChI=1/C14H13N3/c1-10-6-7-17-9-13(16-14(17)8-10)11-2-4-12(15)5-3-11/h2-9H,15H2,1H3
64730-34-3Relevant articles and documents
Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N′-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo
Xu, Ying,Wang, Ning-Yu,Song, Xue-Jiao,Lei, Qian,Ye, Ting-Hong,You, Xin-Yu,Zuo, Wei-Qiong,Xia, Yong,Zhang, Li-Dan,Yu, Luo-Ting
, p. 4333 - 4343 (2015/08/03)
FLT3 inhibitors have been explored as a viable therapy for acute myeloid leukemia (AML). However, the clinical outcomes of these FLT3 inhibitors were underwhelming except AC220. Therefore, the development of novel FLT3 inhibitors with high potency against
